Julie Green Sells 22,355 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 22,355 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $0.72, for a total value of $16,095.60. Following the sale, the insider directly owned 187,362 shares in the company, valued at $134,900.64. The trade was a 10.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

• On Tuesday, August 18th, Julie Green sold 18,425 shares of Invivyd stock. The shares were sold at an average price of $0.84, for a total value of $15,477.00.

Invivyd Price Performance

NASDAQ:IVVD opened at $0.96 on Thursday. The firm has a market capitalization of $282.82 million, a price-to-earnings ratio of -2.91 and a beta of 0.71. The business has a 50 day simple moving average of $0.77 and a 200-day simple moving average of $1.23. Invivyd, Inc. has a 1 year low of $0.48 and a 1 year high of $3.07.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The company had revenue of $14.29 million for the quarter, compared to the consensus estimate of $14.40 million. As a group, analysts expect that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IVVD has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday. BTIG Research restated a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $8.00.

Hedge Funds Weigh In On Invivyd

A number of large investors have recently bought and sold shares of IVVD. Eventide Asset Management LLC bought a new position in Invivyd in the 4th quarter valued at $14,349,000. Perceptive Advisors LLC bought a new stake in shares of Invivyd during the fourth quarter worth $53,809,000. BVF Inc. IL bought a new stake in shares of Invivyd during the fourth quarter worth $48,227,000. UBS Group AG boosted its stake in shares of Invivyd by 683.8% during the fourth quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock valued at $2,596,000 after purchasing an additional 916,842 shares during the period. Finally, Chicago Partners Investment Group LLC purchased a new stake in shares of Invivyd during the first quarter valued at $25,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd News Summary

Here are the key news stories impacting Invivyd this week:

• Positive Sentiment: Several research firms maintain Buy ratings on Invivyd, and the stock’s average analyst price target remains substantially above its current trading range. Institutional ownership is also significant, with investors holding about 70% of the outstanding shares. MarketBeat Invivyd analyst and institutional data
• Neutral Sentiment: Robert Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold Invivyd shares on August 17 or 18 at approximately $0.72 or $0.84. The transactions reduced their individual holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings indicate that the sales were made to cover tax-withholding obligations associated with vested equity awards. That makes them less bearish than discretionary open-market sales intended to reduce exposure.
• Negative Sentiment: The unusually broad participation by multiple insiders could still create a short-term sentiment overhang, particularly for Invivyd’s relatively small market capitalization. Investors also continue to face fundamental risks: the company recently missed quarterly earnings expectations, reported a net loss, and remains dependent on the development and commercialization of its antibody-based infectious-disease pipeline.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.